Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX EBITDA Margin

EBITDA as a percentage of revenue.

No reported EBITDA Margin figures are available to summarize.

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How PCVX compares with its peers on the latest reported figures

PCVX Competitors Peer median
EBITDA Margin for PCVX and competitors
Company Period LTM level YoY 3-year change
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
NVAXNovavax, Inc.LTM Mar 2026-7.1% -51.3 pp+81.6 pp
VALNValneva SELTM Mar 2026-57.7% -35.6 pp+0.1 pp
MRNAModerna, Inc.LTM Sep 2026-97.2% +35.0 pp-184.1 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
IBRXImmunityBio, Inc.LTM Sep 2026-550.8% -269.0 pp+146419.7 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding PCVX) -77.4%-23.0 pp-6.8 pp

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development78.41M169.45M332.34M476.64M794.31M
Selling, General & Admin25.26M39.81M60.7M92.9M129.37M
Operating Expenses103.67M232.26M468.04M569.55M923.68M
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
EBITDA(96.61M)(214.03M)(392.1M)(448.08M)(741.77M)
EBITDA Margin—————
Operating Income(103.67M)(232.26M)(468.04M)(569.55M)(923.68M)
Operating Margin—————
Interest Income344K8.36M62.91M109.99M119.72M
Interest Expense7K2K000
Other Income / Expenses3.59M8.77M65.78M105.62M157.05M
Income Before Tax(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Net Margin—————
EPS (Basic)(1.93)(3.44)(4.14)(3.80)(5.63)
EPS (Diluted)(1.93)(3.44)(4.14)(3.80)(5.63)
Weighted Avg Shares51.92M64.88M97.16M122M136.09M
Weighted Avg Shares (Diluted)51.92M64.88M97.16M122M136.09M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.